Structure of crenezumab complex with aβ shows loss of β-hairpin

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ultsch, Mark ^a   Li, Bing ^a   Maurer, Till ^a   Mathieu, Mary ^a   Adolfsson, Oskar ^b   Muhs, Andreas ^b   Pfeifer, Andrea ^b   Pihlgren, Maria ^b   Bainbridge, Travis W ^a   Reichelt, Mike ^a   Ernst, James A ^a   Eigenbrot, Charles ^a   Fuh, Germaine ^a   Atwal, Jasvinder K ^a   Watts, Ryan J ^a   Wang, Weiru ^a  

^a GENENTECH INC   (United States)

^b AC IMMUNE SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007008358     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39374     Document Type: Article

References (48)

1. Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimers Dement 11, 332-384 (2015
2. Price, M., et al. World Alzheimer report 2015: the global impact of dementia. Alzheimer's Disease International (2015
3. Selkoe, D. J., Abraham, C. R., Podlisny, M. B., & Duffy, L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 46, 1820-1834 (1986
4. Walsh, D. M., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-Term potentiation in vivo. Nature 416, 535-539 (2002
5. Murakami, K. Conformation-specific antibodies to target amyloid beta oligomers and their application to immunotherapy for Alzheimer's disease. Biosci Biotechnol Biochem 78, 1293-1305 (2014
6. Haass, C., & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature reviews. Molecular cell biology 8, 101-112 (2007
7. Wang, Z. X., Tan, L., Liu, J., & Yu, J. T. The Essential Role of Soluble Abeta Oligomers in Alzheimer's Disease. Molecular neurobiology 53, 1905-1924 (2016
8. Benilova, I., Karran, E., & De Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nature neuroscience 15, 349-357 (2012
9. Sperling, R. A., et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6, 228fs213 (2014
10. Adolfsson, O., et al. An effector-reduced anti-beta-Amyloid antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32, 9677-9689 (2012
11. Heneka, M. T., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 14, 388-405 (2015
12. Xing, B., Bachstetter, A. D., & Van Eldik, L. J. Microglial p38alpha MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFalpha. Mol Neurodegener 6, 84 (2011
13. Fuller, J. P., Stavenhagen, J. B., & Teeling, J. L. New roles for Fc receptors in neurodegeneration-The impact on Immunotherapy for Alzheimer's Disease. Front Neurosci 8, 235 (2014
14. Wilcock, D. M., et al. Deglycosylated anti-Amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci 26, 5340-5346 (2006
15. Cummings, J. C. W., et al. A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. Alzheimer's Dementia 10 (2014
16. Moreth, J., Mavoungou, C., & Schindowski, K. Passive anti-Amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun & Ageing 10, 18 (2013
17. Bussiere, T., et al. inventors; Biogen Idec International Neuroscience Gmbh, assignee. A Method Of Reducing Brain Amyloid Plaques Using Anti-Aβ Antibodies. Uniuted States patent application WO2014089500 A1. 2014 Jun 12
18. Schenk, D. B. B. CA. Passive immunization treatment of Alzheimer's disease. United States patent (2004
19. Leyhe, T., et al. Modulation of beta-Amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study. Alzheimers Res Ther 6, 19 (2014
20. Holtzman, D. M., et al. Humanized Antibodies That Sequester Amyloid Beta Peptide. Uniuted States patent US 8338120. 2002 Dec 25
21. La Porte, S. L., et al. Structural basis of C-Terminal beta-Amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol 421, 525-536 (2012
22. Bohrmann, B., et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28, 49-69 (2012
23. Miles, L. A., et al. Amyloid-beta-Anti-Amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J Mol Biol 377, 181-192 (2008
24. Miles, L. A., Crespi, G. A., Doughty, L., & Parker, M. W. Bapineuzumab captures the N-Terminus of the Alzheimer's disease amyloidbeta peptide in a helical conformation. Sci Rep 3, 1302 (2013
25. Crespi, G. A., Hermans, S. J., Parker, M. W., & Miles, L. A. Molecular basis for mid-region amyloid-beta capture by leading Alzheimer's disease immunotherapies. Sci Rep 5, 9649 (2015
26. Eanes, E. D., & Glenner, G. G. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem 16, 673-677 (1968
27. Kirschner, D. A., Abraham, C., & Selkoe, D. J. X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-beta conformation. Proc Natl Acad Sci USA 83, 503-507 (1986
28. Petkova, A. T., et al. A structural model for Alzheimer's beta-Amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci USA 99, 16742-16747 (2002
29. Luhrs, T., et al. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 102, 17342-17347 (2005
30. Paravastu, A. K., Leapman, R. D., Yau, W. M., & Tycko, R. Molecular structural basis for polymorphism in Alzheimer's beta-Amyloid fibrils. Proc Natl Acad Sci USA 105, 18349-18354 (2008
31. Gu, L., et al. Antiparallel triple-strand architecture for prefibrillar Abeta42 oligomers. J Biol Chem 289, 27300-27313 (2014
32. Xiao, Y., et al. Abeta(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol 22, 499-505 (2015
33. Tycko, R. Alzheimer's disease: Structure of aggregates revealed. Nature 537, 492-493 (2016
34. Walti, M. A., et al. Atomic-resolution structure of a disease-relevant Abeta(1-42) amyloid fibril. Proc Natl Acad Sci USA 113, E4976-4984 (2016
35. Colvin, M. T., et al. Atomic Resolution Structure of Monomorphic Abeta42 Amyloid Fibrils. J Am Chem Soc 138, 9663-9674 (2016
36. Sciarretta, K. L., Gordon, D. J., Petkova, A. T., Tycko, R., & Meredith, S. C. Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. Biochemistry 44, 6003-6014 (2005
37. Murakami, K., et al. Monoclonal antibody against the turn of the 42-residue amyloid beta-protein at positions 22 and 23. ACS Chem Neurosci 1, 747-756 (2010
38. Lawrence, M. C., & Colman, P. M. Shape complementarity at protein/protein interfaces. J Mol Biol 234, 946-950 (1993
39. Kay, L. E., Keifer, P., & Saarinen, T. Pure Absorption Gradient Enhanced Heteronuclear Single Quantum Correlation Spectroscopy with Improved Sensitivity. J Am Chem Soc 114, 10663-10665 (1992
40. Fawzi, N. L., Ying, J., Ghirlando, R., Torchia, D. A., & Clore, G. M. Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed by solution NMR. Nature 480, 268-272 (2011
41. Masuda, Y., et al. Identification of physiological and toxic conformations in Abeta42 aggregates. Chembiochem 10, 287-295 (2009
42. Tomaselli, S., et al. The alpha-To-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chembiochem 7, 257-267 (2006
43. Otwinowski, Z., & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromolecular Crystallography, Pt A 276, 307-326 (1997
44. McCoy, A. J., et al. Phaser crystallographic software. J Appl Crystallogr 40, 658-674 (2007
45. Atwal, J. K., et al. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med 3, 84ra43 (2011
46. Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010
47. Murshudov, G. N., Vagin, A. A., & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255 (1997
48. Adams, P. D., et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66, 213-221 (2010